{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T17:56:45Z","timestamp":1793555805909,"version":"4.5.0"},"reference-count":184,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The pathogenesis of gouty arthritis (GA) begins with the deposition of monosodium urate (MSU) crystals in the joints. This crystal deposition triggers a critical inflammatory response by activating the NLRP3 inflammasome, which in turn drives the maturation and release of pro-inflammatory cytokines such as IL-1\u03b2. Beyond this well-defined inflammatory axis, metabolic dysregulation is increasingly recognized as a core component of GA pathogenesis. This paper systematically reviews the crosstalk between metabolic signaling and the NLRP3 inflammasome in GA, elucidating how MSU crystals serve as a bridge between hyperuricemia (HUA) and innate immune activation. Furthermore, we elaborate the dual role of metabolic factors: acting both as \u201cprimer\u201d and \u201camplifiers\u201d of NLRP3 inflammasome activation, significantly lowering its activation threshold. This mechanistic association offers novel therapeutic insights for GA management: synergistic regulation of metabolic signaling alongside targeted inhibition of NLRP3 inflammasome activation enables more effective therapeutic interventions. Defining gout as a \u201cmetabolic-inflammatory\u201d disorder has led to the development of novel dual-target therapeutic strategies\u2014simultaneously alleviating inflammatory symptoms while regulating metabolic abnormalities. Such approaches hold significant promise for effectively preventing and controlling gout attacks, whilst reducing the risk of long-term complications.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1761121","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:27:14Z","timestamp":1773293234000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The interplay between NLRP3 inflammasome and metabolic signals in gouty arthritis"],"prefix":"10.3389","volume":"17","author":[{"given":"Dongyi","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kunming Municipal Hospital of Traditional Chinese Medicine","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyi","family":"Pu","sequence":"additional","affiliation":[{"name":"Chengdu Institute of Biology, Chinese Academy of Sciences","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kunming Municipal Hospital of Traditional Chinese Medicine","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kunming Municipal Hospital of Traditional Chinese Medicine","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kunming Municipal Hospital of Traditional Chinese Medicine","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoke","family":"Shi","sequence":"additional","affiliation":[{"name":"Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.3390\/jcm10091880","article-title":"Autoinflammatory features in gouty arthritis","volume":"10","author":"Galozzi","year":"2021","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00117-6","article-title":"Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"6","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez196","article-title":"Gout and hyperuricaemia in the USA: prevalence and trends","volume":"58","author":"Singh","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.12.019","article-title":"Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study","volume":"127","author":"Neogi","year":"2014","journal-title":"Am J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/biom11020280","article-title":"Why does hyperuricemia not necessarily induce gout","volume":"11","author":"Zhang","year":"2021","journal-title":"Biomolecules"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s11926-013-0392-5","article-title":"Mechanisms of spontaneous resolution of acute gouty inflammation","volume":"16","author":"Steiger","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.10.003","article-title":"The NLRP3 inflammasome: regulation by metabolic signals","volume":"43","author":"Olona","year":"2022","journal-title":"Trends Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","article-title":"The crystallization of monosodium urate","volume":"16","author":"Martillo","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2015.08.109","article-title":"Regulation of uric acid metabolism and excretion","volume":"213","author":"Maiuolo","year":"2016","journal-title":"Int J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/ar3199","article-title":"Epidemiology of gout","volume":"12","author":"Roddy","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-014-0413-6","article-title":"Anti-hyperuricemic and nephroprotective effects of Rhizoma Dioscoreae septemlobae extracts and its main component dioscin via regulation of mOAT1, mURAT1 and mOCT2 in hypertensive mice","volume":"37","author":"Su","year":"2014","journal-title":"Arch Pharm Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jbspin.2010.02.027","article-title":"The genetic basis of hyperuricaemia and gout","volume":"78","author":"Merriman","year":"2011","journal-title":"Joint Bone Spine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.713710","article-title":"Genetic and physiological effects of insulin on human urate homeostasis","volume":"12","author":"Mandal","year":"2021","journal-title":"Front Physiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0239-5","article-title":"Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes","volume":"48","author":"Zhang","year":"2015","journal-title":"Endocrine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2741\/3950","article-title":"Uric acid, hyperuricemia and vascular diseases","volume":"17","author":"Jin","year":"2012","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179221","article-title":"Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease","volume":"22","author":"Yanai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42344","article-title":"Uric acid transport and disease","volume":"120","author":"So","year":"2010","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellbi.2004.11.024","article-title":"Expression of the GLUT1 and GLUT9 facilitative glucose transporters in embryonic chondroblasts and mature chondrocytes in ovine articular cartilage","volume":"29","author":"Mobasheri","year":"2005","journal-title":"Cell Biol Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2020.12.006","article-title":"Molecular pathophysiology of uric acid homeostasis","volume":"40","author":"Estiverne","year":"2020","journal-title":"Semin Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5ra11","DOI":"10.1126\/scitranslmed.3000237","article-title":"Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population","volume":"1","author":"Matsuo","year":"2009","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136678","article-title":"The role of ABCG2 in the pathogenesis of primary hyperuricemia and gout-an update","volume":"22","author":"Eckenstaler","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021113-170343","article-title":"The molecular physiology of uric acid homeostasis","volume":"77","author":"Mandal","year":"2015","journal-title":"Annu Rev Physiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0004-x","article-title":"An update on the genetics of hyperuricaemia and gout","volume":"14","author":"Major","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1186\/s40001-025-03209-8","article-title":"Molecular interplay between TXNIP and GLUT9 underlies uric acid transport dysregulation in vitro under hyperuricemic stress","volume":"30","author":"Zhu","year":"2025","journal-title":"Eur J Med Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13075-018-1512-4","article-title":"Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K\/Akt signaling pathway","volume":"20","author":"Chen","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"117644","DOI":"10.1016\/j.ejmech.2025.117644","article-title":"Scaffold hopping-based structural modification of tranilast led to the identification of HNW005 as a promising NLRP3 inflammasome and URAT1 dual inhibitor for the treatment of gouty arthritis","volume":"292","author":"Sun","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.125","article-title":"Mechanisms of crystal formation in gout-a structural approach","volume":"11","author":"Pascual","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention","volume":"20","author":"Cambier","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S460333","article-title":"Targeting neutrophil extracellular traps in gouty arthritis: insights into pathogenesis and therapeutic potential","volume":"17","author":"Li","year":"2024","journal-title":"J Inflammation Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","article-title":"Regulation and function of NF-kappaB transcription factors in the immune system","volume":"27","author":"Vallabhapurapu","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215315","article-title":"2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout","volume":"79","author":"Richette","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"108107","DOI":"10.1016\/j.intimp.2021.108107","article-title":"Tetrahydropalmatine attenuates MSU crystal-induced gouty arthritis by inhibiting ROS-mediated NLRP3 inflammasome activation","volume":"100","author":"Wang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13075-016-1012-3","article-title":"Monosodium urate crystals induce oxidative stress in human synoviocytes","volume":"18","author":"Zamudio-Cuevas","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1186\/ar2930","article-title":"High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals","volume":"12","author":"Scanu","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031651","article-title":"Identification of NLRP3(PYD) homo-oligomerization inhibitors with anti-inflammatory activity","volume":"23","author":"Moasses Ghafary","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.02.008","article-title":"Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes","volume":"156","author":"Lu","year":"2014","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and regulation of the inflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/1753425913484374","article-title":"Caspase-1: the inflammasome and beyond","volume":"20","author":"Sollberger","year":"2014","journal-title":"Innate Immun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nature18590","article-title":"Pore-forming activity and structural autoinhibition of the gasdermin family","volume":"535","author":"Ding","year":"2016","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01192-4","article-title":"Caspase-11 interaction with NLRP3 potentiates the noncanonical activation of the NLRP3 inflammasome","volume":"23","author":"Moretti","year":"2022","journal-title":"Nat Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.it.2018.01.009","article-title":"Orchestration of NLRP3 inflammasome activation by ion fluxes","volume":"39","author":"Gong","year":"2018","journal-title":"Trends Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402195","article-title":"Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration","volume":"14","author":"P\u00e9trilli","year":"2007","journal-title":"Cell Death Differ"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter","volume":"38","author":"Mu\u00f1oz-Planillo","year":"2013","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"104419","DOI":"10.1016\/j.ebiom.2022.104419","article-title":"Danger signals released during cold ischemia storage activate NLRP3 inflammasome in myeloid cells and influence early allograft function in liver transplantation","volume":"87","author":"Lucas-Ruiz","year":"2023","journal-title":"EBioMedicine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.taap.2017.01.012","article-title":"Phagolysosome acidification is required for silica and engineered nanoparticle-induced lysosome membrane permeabilization and resultant NLRP3 inflammasome activity","volume":"318","author":"Jessop","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1631","article-title":"Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization","volume":"9","author":"Hornung","year":"2008","journal-title":"Nat Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0761-3","article-title":"PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation","volume":"564","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12964-025-02426-2","article-title":"The impact of post-translational modifications and subcellular localization on NLRP3 inflammasome activation: A systematic review","volume":"23","author":"Zhang","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1038\/s41467-018-05321-2","article-title":"SUMO-mediated regulation of NLRP3 modulates inflammasome activity","volume":"9","author":"Barry","year":"2018","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2025.02.008","article-title":"Insights into palmitoylation-mediated regulation of inflammasomes","volume":"46","author":"Jiang","year":"2025","journal-title":"Trends Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"8396","DOI":"10.1038\/s41467-023-44203-0","article-title":"Acetylation is required for full activation of the NLRP3 inflammasome","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161935","article-title":"Posttranslational ISGylation of NLRP3 by HERC enzymes facilitates inflammasome activation in models of inflammation","volume":"133","author":"Qin","year":"2023","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","first-page":"103655","DOI":"10.1016\/j.jff.2019.103655","article-title":"Vanillylacetone attenuates NLRP3 inflammasome mediated immune responses in murine bone marrow derived macrophages via NLRP3 alkylation","volume":"64","author":"Kim","year":"2019","journal-title":"J Funct Foods"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051219","article-title":"The roles of endoplasmic reticulum in NLRP3 inflammasome activation","volume":"9","author":"Zhou","year":"2020","journal-title":"Cells"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nat Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-01054-4","article-title":"FAAH served a key membrane-anchoring and stabilizing role for NLRP3 protein independently of the endocannabinoid system","volume":"30","author":"Zhu","year":"2023","journal-title":"Cell Death Differ"},{"key":"B69","doi-asserted-by":"publisher","first-page":"15986","DOI":"10.1038\/ncomms15986","article-title":"MARK4 regulates NLRP3 positioning and inflammasome activation through a microtubule-dependent mechanism","volume":"8","author":"Li","year":"2017","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22585","article-title":"Study for updated gout classification criteria: identification of features to classify gout","volume":"67","author":"Taylor","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.861399","article-title":"Natural products as a novel therapeutic strategy for NLRP3 inflammasome-mediated gout","volume":"13","author":"Lee","year":"2022","journal-title":"Front Pharmacol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nature01991","article-title":"Molecular identification of a danger signal that alerts the immune system to dying cells","volume":"425","author":"Shi","year":"2003","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.chom.2008.08.007","article-title":"The caspase-1 inflammasome: a pilot of innate immune responses","volume":"4","author":"Yu","year":"2008","journal-title":"Cell Host Microbe"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.3390\/nu14173525","article-title":"Gout and diet: A comprehensive review of mechanisms and management","volume":"14","author":"Zhang","year":"2022","journal-title":"Nutrients"},{"key":"B75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/tropicalmed9010013","article-title":"Pro-inflammatory and anti-inflammatory interleukins in infectious diseases: A comprehensive review","volume":"9","author":"Al-Qahtani","year":"2024","journal-title":"Trop Med Infect Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28075","article-title":"MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals","volume":"116","author":"Chen","year":"2006","journal-title":"J Clin Invest"},{"key":"B77","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2022.29.3.140","article-title":"The mechanism of the NLRP3 inflammasome activation and pathogenic implication in the pathogenesis of gout","volume":"29","author":"Kim","year":"2022","journal-title":"J Rheum Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.155","article-title":"Inflammation in gout: mechanisms and therapeutic targets","volume":"13","author":"So","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1427607","DOI":"10.1155\/2022\/1427607","article-title":"NLRP3 susceptible gene polymorphisms in patients with primary gouty arthritis and hyperuricemia","volume":"2022","author":"Zhang","year":"2022","journal-title":"BioMed Res Int"},{"key":"B81","article-title":"rs3806268 of NLRP3 gene polymorphism is associated with the development of primary gout","volume":"8","author":"Deng","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3900-6","article-title":"Association of NLRP3 polymorphisms with susceptibility to primary gouty arthritis in a Chinese Han population","volume":"37","author":"Zhang","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.4238\/2015.December.9.10","article-title":"Investigation on the association between NLRP3 gene polymorphisms and susceptibility to primary gout","volume":"14","author":"Wang","year":"2015","journal-title":"Genet Mol Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206564","article-title":"Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra","volume":"75","author":"Cri\u0219an","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B85","doi-asserted-by":"publisher","first-page":"39884","DOI":"10.1038\/srep39884","article-title":"Soluble uric acid activates the NLRP3 inflammasome","volume":"7","author":"Braga","year":"2017","journal-title":"Sci Rep"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.08.013","article-title":"Free fatty acids as modulators of the NLRP3 inflammasome in obesity\/type 2 diabetes","volume":"92","author":"Legrand-Poels","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00011.2008","article-title":"Alcohol and lipid metabolism","volume":"295","author":"Sozio","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/86.5.1515","article-title":"Fasting induces changes in peripheral blood mononuclear cell gene expression profiles related to increases in fatty acid beta-oxidation: functional role of peroxisome proliferator activated receptor alpha in human peripheral blood mononuclear cells","volume":"86","author":"Bouwens","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04903-9","article-title":"Study on the relationship between FFA and gout flare","volume":"39","author":"Pei","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28898","article-title":"TLR4 links innate immunity and fatty acid-induced insulin resistance","volume":"116","author":"Shi","year":"2006","journal-title":"J Clin Invest"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/art.27667","article-title":"Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1\u03b2 production via the ASC\/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis","volume":"62","author":"Joosten","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/nri3446","article-title":"The history of Toll-like receptors - redefining innate immunity","volume":"13","author":"O\u2019Neill","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2022","article-title":"Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen","year":"2011","journal-title":"Nat Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1194\/jlr.M037861","article-title":"Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes\/macrophages","volume":"54","author":"L\u2019Homme","year":"2013","journal-title":"J Lipid Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.05.015","article-title":"Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation","volume":"38","author":"Yan","year":"2013","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1159\/000329954","article-title":"Inhibitory effect of unsaturated fatty acids on saturated fatty acid-induced apoptosis in human pancreatic \u03b2-cells: activation of caspases and ER stress induction","volume":"27","author":"N\u011bmcov\u00e1-F\u00fcrstov\u00e1","year":"2011","journal-title":"Cell Physiol Biochem"},{"key":"B97","doi-asserted-by":"publisher","first-page":"101182","DOI":"10.1016\/j.plipres.2022.101182","article-title":"Lipid-protein interactions regulating the canonical and the non-canonical NLRP3 inflammasome","volume":"87","author":"Pizzuto","year":"2022","journal-title":"Prog Lipid Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3390\/jpm12040605","article-title":"Association between gout and dyslipidemia: A nested case-control study using a national health screening cohort","volume":"12","author":"Choi","year":"2022","journal-title":"J Pers Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11883-025-01323-w","article-title":"Cholesterol crystals as triggers of NLRP3 inflammasome activation in atherosclerosis","volume":"27","author":"Yalcinkaya","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e11765","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajam\u00e4ki","year":"2010","journal-title":"PloS One"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.11.008","article-title":"Cholesterol accumulation in CD11c(+) immune cells is a causal and targetable factor in autoimmune disease","volume":"45","author":"Ito","year":"2016","journal-title":"Immunity"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.cmet.2017.04.005","article-title":"Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity","volume":"25","author":"Westerterp","year":"2017","journal-title":"Cell Metab"},{"key":"B104","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.immuni.2018.08.021","article-title":"Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages","volume":"49","author":"Guo","year":"2018","journal-title":"Immunity"},{"key":"B105","doi-asserted-by":"publisher","first-page":"100534","DOI":"10.1016\/j.jlr.2024.100534","article-title":"Cholesterol trafficking to the ER leads to the activation of CaMKII\/JNK\/NLRP3 and promotes atherosclerosis","volume":"65","author":"Yalcinkaya","year":"2024","journal-title":"J Lipid Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf2489","article-title":"Mitochondrial C5aR1 activity in macrophages controls IL-1\u03b2 production underlying sterile inflammation","volume":"6","author":"Niyonzima","year":"2021","journal-title":"Sci Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-022-07408-y","article-title":"NF-\u03baB\/ABCA1 pathway aggravates ox-LDL-induced cell pyroptosis by activation of NLRP3 inflammasomes in THP-1-derived macrophages","volume":"49","author":"Li","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B108","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00011-013-0667-3","article-title":"OxLDL-induced IL-1 beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation","volume":"63","author":"Liu","year":"2014","journal-title":"Inflammation Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S231916","article-title":"Ox-LDL causes endothelial cell injury through ASK1\/NLRP3-mediated inflammasome activation via endoplasmic reticulum stress","volume":"14","author":"Hang","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.117.032636","article-title":"Cholesterol efflux pathways suppress inflammasome activation, NETosis, and atherogenesis","volume":"138","author":"Westerterp","year":"2018","journal-title":"Circulation"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.909810","article-title":"CD36 promotes podocyte apoptosis by activating the pyrin domain-containing-3 (NLRP3) inflammasome in primary nephrotic syndrome","volume":"24","author":"Yang","year":"2018","journal-title":"Med Sci Monit"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.11.025","article-title":"Inhibition of the NLRP3 inflammasome attenuates foam cell formation of THP-1 macrophages by suppressing ox-LDL uptake and promoting cholesterol efflux","volume":"495","author":"Chen","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B113","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e1358","DOI":"10.1097\/MD.0000000000001358","article-title":"Individuals with type 2 diabetes mellitus are at an increased risk of gout but this is not due to diabetes: A population-based cohort study","volume":"94","author":"Wijnands","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835d951e","article-title":"Metabolic syndrome, diabetes, and hyperuricemia","volume":"25","author":"Li","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"10281","DOI":"10.1038\/s41598-022-11094-y","article-title":"Possible role of insulin resistance in activation of plasma xanthine oxidoreductase in health check-up examinees","volume":"12","author":"Kurajoh","year":"2022","journal-title":"Sci Rep"},{"key":"B117","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.1184003","article-title":"The NLRP3 inflammasome: a sensor for metabolic danger","volume":"327","author":"Schroder","year":"2010","journal-title":"Science"},{"key":"B118","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/eji.201445427","article-title":"Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal","volume":"46","author":"Mills","year":"2016","journal-title":"Eur J Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00749-7","article-title":"Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways","volume":"43","author":"Zhong","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2013.02.009","article-title":"ATP-P2X4 signaling mediates NLRP3 inflammasome activation: a novel pathway of diabetic nephropathy","volume":"45","author":"Chen","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"6973175","DOI":"10.1155\/2016\/6973175","article-title":"High glucose and lipopolysaccharide prime NLRP3 inflammasome via ROS\/TXNIP pathway in mesangial cells","volume":"2016","author":"Feng","year":"2016","journal-title":"J Diabetes Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"678627","DOI":"10.1155\/2013\/678627","article-title":"The NLRP3 Inflammasome as a novel player of the intercellular crosstalk in metabolic disorders","volume":"2013","author":"Benetti","year":"2013","journal-title":"Mediators Inflamm"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.931087","article-title":"Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway via IRS2-proteasome degradation","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13628","article-title":"Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming","volume":"169","author":"Chen","year":"2023","journal-title":"Immunology"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13067","article-title":"Advanced glycation end products regulate anabolic and catabolic activities via NLRP3-inflammasome activation in human nucleus pulposus cells","volume":"21","author":"Song","year":"2017","journal-title":"J Cell Mol Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-EWRR2019.142","article-title":"P160 The first phase 2A proof-of-concept study of a selective NLRP3 inflammasome inhibitor, dapansutrile\u2122 (OLT1177\u2122), in acute gout","volume":"78","author":"Jansen","year":"2019","journal-title":"Ann Rheumatic Diseases"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1731165","article-title":"Dapansutrile in multidisciplinary therapeutic applications: mechanisms and clinical perspectives","volume":"16","author":"Bai","year":"2025","journal-title":"Front Pharmacol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e00291","DOI":"10.1002\/prp2.291","article-title":"Uricosuric targets of tranilast","volume":"5","author":"Mandal","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat Commun"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J Exp Med"},{"key":"B134","doi-asserted-by":"publisher","first-page":"101015","DOI":"10.1016\/j.xinn.2025.101015","article-title":"Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial","volume":"6","author":"Xue","year":"2025","journal-title":"Innovation (Camb)"},{"key":"B135","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12967-025-06072-7","article-title":"Firsekibart in acute gouty arthritis","volume":"23","author":"Xue","year":"2025","journal-title":"J Transl Med"},{"key":"B136","article-title":"Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders","volume":"11","author":"Church","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"B137","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.880653","article-title":"Canakinumab for gout: a specific, patient-profiled indication","volume":"10","author":"Perez-Ruiz","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B140","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2796.2010.02313.x","article-title":"Blocking interleukin-1\u03b2 in acute and chronic autoinflammatory diseases","volume":"269","author":"Dinarello","year":"2011","journal-title":"J Intern Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key402","article-title":"Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial","volume":"58","author":"Janssen","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.03.015","article-title":"Effectiveness and safety of anakinra in gout patients with stage 4\u20135 chronic kidney disease or kidney transplantation: A multicentre, retrospective study","volume":"85","author":"Loustau","year":"2018","journal-title":"Joint Bone Spine"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/art.41699","article-title":"A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nm811","article-title":"Cytokine traps: multi-component, high-affinity blockers of cytokine action","volume":"9","author":"Economides","year":"2003","journal-title":"Nat Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/art.33412","article-title":"Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket114","article-title":"Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial","volume":"52","author":"Mitha","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131226","article-title":"Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study","volume":"41","author":"Sundy","year":"2014","journal-title":"J Rheumatol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00775-014-1210-x","article-title":"Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout","volume":"20","author":"Nishino","year":"2015","journal-title":"J Biol Inorg Chem"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S3310","article-title":"Febuxostat in the management of hyperuricemia and chronic gout: a review","volume":"4","author":"Hu","year":"2008","journal-title":"Ther Clin Risk Manage"},{"key":"B151","article-title":"Allopurinol","volume-title":"StatPearls","author":"Qurie","year":"2025"},{"key":"B152","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.1038\/ncomms7555","article-title":"Xanthine oxidoreductase regulates macrophage IL1\u03b2 secretion upon NLRP3 inflammasome activation","volume":"6","author":"Ives","year":"2015","journal-title":"Nat Commun"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.09.032","article-title":"Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress","volume":"427","author":"Tsuda","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.2174\/1871523011312010011","article-title":"Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation","volume":"12","author":"Sab\u00e1n-Ruiz","year":"2013","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912059107","article-title":"Induction of fatty acid synthesis is a key requirement for phagocytic differentiation of human monocytes","volume":"107","author":"Ecker","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.551051","article-title":"Glucose-dependent de novo lipogenesis in B lymphocytes: a requirement for atp-citrate lyase in lipopolysaccharide-induced differentiation","volume":"289","author":"Dufort","year":"2014","journal-title":"J Biol Chem"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1532021","article-title":"Fatty acid synthase inhibition improves hypertension-induced erectile dysfunction by suppressing oxidative stress and NLRP3 inflammasome-dependent pyroptosis through activating the Nrf2\/HO-1 pathway","volume":"15","author":"Luan","year":"2024","journal-title":"Front Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00289","article-title":"Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity","volume":"8","author":"Geeraerts","year":"2017","journal-title":"Front Immunol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"115549","DOI":"10.1016\/j.fct.2025.115549","article-title":"Fatty acid oxidation contributed to NLRP3 inflammasome activation caused by N-nitrosamines co-exposure","volume":"202","author":"Zhang","year":"2025","journal-title":"Food Chem Toxicol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"114634","DOI":"10.1016\/j.bcp.2021.114634","article-title":"Pharmacological inhibition of fatty acid oxidation reduces atherosclerosis progression by suppression of macrophage NLRP3 inflammasome activation","volume":"190","author":"Hohensinner","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665118002872","article-title":"Dietary modulation of energy homoeostasis and metabolic-inflammation","volume":"78","author":"Roche","year":"2019","journal-title":"Proc Nutr Soc"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00220","article-title":"Fish oil derived omega 3 fatty acids suppress adipose NLRP3 inflammasome signaling in human obesity","volume":"3","author":"Lee","year":"2019","journal-title":"J Endocr Soc"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208767","article-title":"Low omega-3 fatty acid levels associate with frequent gout attacks: a case control study","volume":"75","author":"Abhishek","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B165","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/art.21521","article-title":"Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy","volume":"54","author":"Abeles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1124\/mol.116.108100","article-title":"Statins attenuate activation of the NLRP3 inflammasome by oxidized LDL or TNF\u03b1 in vascular endothelial cells through a PXR-dependent mechanism","volume":"92","author":"Wang","year":"2017","journal-title":"Mol Pharmacol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1096999","article-title":"Association between statin use and the risk of gout in patients with hyperlipidemia: A population-based cohort study","volume":"14","author":"Lin","year":"2023","journal-title":"Front Pharmacol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2009.04.002","article-title":"Where are we with probucol: a new life for an old drug","volume":"207","author":"Yamashita","year":"2009","journal-title":"Atherosclerosis"},{"key":"B169","doi-asserted-by":"publisher","first-page":"108397","DOI":"10.1016\/j.intimp.2021.108397","article-title":"Probucol attenuates NF-\u03baB\/NLRP3 signalling and augments Nrf-2 mediated antioxidant defence in nerve injury induced neuropathic pain","volume":"102","author":"Derangula","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2017.1356977","article-title":"Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition","volume":"13","author":"Kim","year":"2017","journal-title":"Autophagy"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-inflammatory compounds parthenolide and Bay 11\u20137082 are direct inhibitors of the inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"J Biol Chem"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S344071","article-title":"NLRP3 inflammasome pharmacological inhibitors in glycyrrhiza for NLRP3-driven diseases treatment: extinguishing the fire of inflammation","volume":"15","author":"Wang","year":"2022","journal-title":"J Inflammation Res"},{"key":"B174","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13075-019-1974-z","article-title":"Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of I\u03baB\u03b1 and blocking mitochondrial damage","volume":"21","author":"Chen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B175","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1038\/s41598-019-40619-1","article-title":"The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1\u03b2-dependent manner in macrophages","volume":"9","author":"Finucane","year":"2019","journal-title":"Sci Rep"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1126\/science.1120781","article-title":"The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin","volume":"310","author":"Shaw","year":"2005","journal-title":"Science"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12812","article-title":"Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes","volume":"19","author":"Wu","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin--mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-01702-4","article-title":"NLRP3 inflammasomes pathway: a key target for Metformin","volume":"33","author":"Hosseini","year":"2025","journal-title":"Inflammopharmacology"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27261","article-title":"Inhibition of glycolysis alleviates lipopolysaccharide-induced acute lung injury in a mouse model","volume":"234","author":"Zhong","year":"2019","journal-title":"J Cell Physiol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1038\/ncomms5436","article-title":"PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis","volume":"5","author":"Yang","year":"2014","journal-title":"Nat Commun"},{"key":"B182","doi-asserted-by":"publisher","first-page":"13280","DOI":"10.1038\/ncomms13280","article-title":"PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation","volume":"7","author":"Xie","year":"2016","journal-title":"Nat Commun"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.630380","article-title":"Lactic acid fermentation is required for NLRP3 inflammasome activation","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.abb.2019.06.010","article-title":"Chaetocin attenuates gout in mice through inhibiting HIF-1\u03b1 and NLRP3 inflammasome-dependent IL-1\u03b2 secretion in macrophages","volume":"670","author":"Mian","year":"2019","journal-title":"Arch Biochem Biophys"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1761121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:27:16Z","timestamp":1773293236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1761121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":184,"alternative-id":["10.3389\/fimmu.2026.1761121"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1761121","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1761121"}}